drugset / Trial / NCT00927875
A Study of BMS-833923 With Carboplatin and Etoposide Followed by BMS-833923 Alone in Subjects With Extensive-Stage Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to determine the maximum tolerated dose (MTD) of BMS-833923 administered in combination with carboplatin and etoposide followed by BMS-833923 alone in subjects with extensive-stage Small Cell Lung Cancer (SCLC).
Timeline
- Start
- 2010-02
- Primary completion
- 2012-09
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-833923 | Small molecule | 30 mg | Oral |
| Background | Carboplatin | Small molecule | 5 mg/ml | Intravenous |
| Background | Etoposide | Small molecule | 100 mg/m2 | Intravenous |